Things are always changing on Wall Street. Share prices fluctuate, new players make their market debut, the macroeconomic environment is shaken and long-term trends shift. One thing remains the same, however: growth is the name of the game. Growth stocks are consistently on investors’ wish lists due to their return potential. This growth potential is above the norm as these games have seen some spectacular gains back in 2020 and the upward trend will continue for the long term. Knowing what you’re looking for is one thing, but how are investors supposed to find these opportunities? One strategy is to look to the pros on Wall Street. With this in mind, according to the analyst community, we used TipRanks’ database in our search for exciting growth names. Any analyst-backed ticker, limited to three stocks that match the bill, can make further gains on top of the impressive year-to-date increases. Here are all the details. Sunnova Energy International (NOVA) First, we have Sunnova Energy International, one of the leading providers of solar and energy storage services for private households. Although it’s already up 160% since the start of the year, several analysts believe that this name offers more wiggle room. After speaking to NOVA founder and CEO John Berger, five-star analyst Joseph Osha of JMP Securities is even more confident about its long-term growth prospects and notes that the stock appears to be significantly undervalued. The analyst particularly highlights the storage business and believes this is a key strength point. “NOVA has effectively increased storage accumulation rates and managed to do well with its dealer-oriented business model. The demand environment for memory has intensified over the past 60 days and we believe we may be at a turning point for the industry, ”commented Osha. If you take a closer look at the attachment rates, the number was 34% in the second quarter. Part of that strong result was due to the company’s entry into island markets. Berger mentioned that the investment rates in Hawaii, Guam, Saipan, and Puerto Rico are actually 100%. In addition, rates are improving in Texas and Florida. Osha explained: “If you put all of this together, you get a figure of 34% that Mr. Berger believes will grow, albeit with very different dynamics in different markets. We also note that NOVA sells storage to existing customers and these sales are not included in the stated attachment rate. “According to Osha, NOVA’s relationships with Tesla and Generac are distinctive because they also select the ideal dealer partners. In addition, the overall memory market appears to be solid and cell manufacturers are struggling to keep up with demand. To this end, Berger argues that the space “is as strong as you think as investment rates continue to rise in new regions and revenue per customer also grows”. While some investors have raised concerns about competition from Sunrun (RUN), Osha believes that the “smaller developers may lose,” although RUN’s approach works relatively well. As a result, the analyst sees room for a higher rating for NOVA. In line with his bullish approach, Osha stayed in the bulls, reiterating a market outperform rating and target price of $ 43. Investors could pocket a 48% profit if that goal is met in the next twelve months. (To see Osha’s track record, click here.) Do other analysts agree? You are. In the last three months only buy ratings have been given, to be precise 10. So the message is clear: NOVA is a strong buy. Given the average target price of $ 33.70, stocks could rise 16% over the next year. (See Sunnova Energy International’s stock analysis on TipRanks) Big Lots (BIG) As a closeout retailer, Big Lots offers its customers everything from groceries and household items to furniture and electronics at an affordable price. With a solid standing in 2021, some members of the street believe the 87% year-to-date gain is just the beginning. The five-star analyst Peter Keith represents Piper Sandler and explains to customers that “the setup will remain very affordable in the future”. The company’s forecast for Q3-Comps was above its estimate, but its request for earnings per share of $ 0.50 to $ 0.70 (versus Keith’s forecast of $ 0.12) came as a big surprise . “Not only has the third quarter been a negative EPS quarter historically, but BIG is also driving massive earnings per share, despite additional rental costs of $ 12 million (from the sale of its DCs) and COVID costs of $ 12 million $ 10 million, “noted Keith. To this end, the analyst has increased its estimate for the fourth quarter. Keith said, “The fourth quarter is going to be pretty strong, the return to discretionary residual items couldn’t be more timed. Our survey work continues to show increased demand for home furnishings and the positive impact of the new Chief Merchant (who joined in late July) has not yet affected the sales trend. “When it comes to remaining stock, new CMO Jack Pestello has helped fuel BIG’s remaining stock efforts. Keith has already noticed convincing offers during shop checks. Additionally, the reduction in promotions should bode well for the retailer. BIG halved the number of promo days in the third quarter of 2020 compared to the third quarter of 2019. While BIG is aiming for flat year-over-year gross margins, Keith believes there is room for upside. In addition, the inventory situation could improve. According to management, most categories had some inventory constraints in the third quarter, but vendors are catching up with demand, especially in key segments like furniture, home office, and small appliances. On top of the good news, a $ 500 million share buyback approval was announced, which Keith said “should add some juice to EPS in the coming quarters.” Everything BIG did about it convinced Keith to keep his overweight rating. On top of the call, he left the price target at $ 75, suggesting upside potential of 40%. (To check out Keith’s track record, click here.) If you turn to the rest of the street, opinions are evenly divided. With 3 buys and 3 holds in the past three months, the word is on the street that BIG is a moderate buy. At $ 60.33, the average target price implies an upside of 12%. (See Big Lots stock analysis on TipRanks) Amicus Therapeutics (FOLD) Finally, we developed Amicus Therapeutics, the therapies for ultra-orphan diseases, including lysosomal storage disorders (LSDs). Up 77% year-to-date, there could be more growth for this healthcare name, according to several street pros. Although next generation enzyme replacement therapy is in place in Phase 3, one of its gene therapeutic assets has received significant attention. During the CNSA conference, FOLD presented additional follow-up data from its Phase 1/2 CLN6 Battens gene therapy program. The program is evaluating AT-GTX-501, its gene therapy for use in CLN6-Batten disease, a deadly disease in which children experience rapid and progressive decline in cognitive and motor function. It has a global population of around 1,000 patients. The presentation included incremental preliminary safety and effectiveness data. Based on the safety data for 13 patients treated with the candidate, the therapy was well tolerated. Note that five patients reported eleven grade 3 SAEs, including four that were considered potentially treatment-related. These included vomiting, fever, and upper abdominal pain, symptoms common with AAV gene therapy administration. Five-star analyst Ritu Baral, who weighs Cowen, argues that the fact that no immunogenicity was observed to AAV9 or CLN6 is an important consideration. In terms of efficacy data, the results for twelve patients who reached the 12 month time point and eight patients who reached the 24 month time point were analyzed against age-adjusted natural history. For the total score for Hamburg motor skills and language (HM & L), which assesses walking ability and language, the average rate of decrease in treated patients was much lower compared to natural history over the same period. If you dig a little deeper, the average rate of decrease in treated subjects at the time of 12 months was 0.4 points compared to 1.2 points in natural history subjects. At the 24-month point in time, the mean rate of decrease in treated subjects was 0.6 points compared with 2.4 points in natural history participants. In addition, management stated that 63% of patients in natural history experienced an additional 2 point decrease in HM&L two years after their first decline, while only 13% of AT-GTX-501 gene therapy recipients experienced the same experienced. What does it all mean? “We consider this update to be incrementally positive and show that the effectiveness of the AT-GTX-501 lasts for up to two years. Interim efficacy results show a nominally statistically significant and very likely clinically meaningful 24 month slowdown in disease progression in CLN6 slats … The natural history dataset was reviewed in a relatively short period of time by the same investigator as the FOLD study, and we believe therefore is likely to be reliable, ”commented Baral. If that is not enough, then natural history control analysis could be enough for registration in the US. “Given the rarity and severity of CLN6, we believe that a prospective PBO-controlled study is not feasible. We believe the natural history of the disease is quickly solidifying into a body of evidence that is of concern to both the FDA and EMA, ”said Baral. With all of this in mind, Baral has high hopes. Along with an outperform rating, she has a target price of $ 31 on the stock. With this goal in mind, the upside potential is 81%. (To see Baral’s track record, click here.) Other analysts appear to support Baral’s view. 3 buys and no holds or sells results in a strong buy consensus rating. Based on the average target price of USD 23.67, the upside potential is 38%. (See Amicus Therapeutics stock analysis on TipRanks.) Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.